Literature DB >> 28490200

Human Bocavirus Type-1 Capsid Facilitates the Transduction of Ferret Airways by Adeno-Associated Virus Genomes.

Ziying Yan1,2, Zehua Feng1, Xingshen Sun1, Yulong Zhang1, Wei Zou3, Zekun Wang3, Chandler Jensen-Cody1, Bo Liang1, Soo-Yeun Park1, Jianming Qiu3, John F Engelhardt1,2.   

Abstract

Human bocavirus type-1 (HBoV1) has a high tropism for the apical membrane of human airway epithelia. The packaging of a recombinant adeno-associated virus 2 (rAAV2) genome into HBoV1 capsid produces a chimeric vector (rAAV2/HBoV1) that also efficiently transduces human airway epithelia. As such, this vector is attractive for use in gene therapies to treat lung diseases such as cystic fibrosis. However, preclinical development of rAAV2/HBoV1 vectors has been hindered by the fact that humans are the only known host for HBoV1 infection. This study reports that rAAV2/HBoV1 vector is capable of efficiently transducing the lungs of both newborn (3- to 7-day-old) and juvenile (29-day-old) ferrets, predominantly in the distal airways. Analyses of in vivo, ex vivo, and in vitro models of the ferret proximal airway demonstrate that infection of this particular region is less effective than it is in humans. Studies of vector binding and endocytosis in polarized ferret proximal airway epithelial cultures revealed that a lack of effective vector endocytosis is the main cause of inefficient transduction in vitro. While transgene expression declined proportionally with growth of the ferrets following infection at 7 days of age, reinfection of ferrets with rAAV2/HBoV1 at 29 days gave rise to approximately 5-fold higher levels of transduction than observed in naive infected 29-day-old animals. The findings presented here lay the foundation for clinical development of HBoV1 capsid-based vectors for lung gene therapy in cystic fibrosis using ferret models.

Entities:  

Keywords:  airway transduction; newborn and juvenile ferret; rAAV2/HBoV1 vector

Mesh:

Substances:

Year:  2017        PMID: 28490200      PMCID: PMC5567599          DOI: 10.1089/hum.2017.060

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  70 in total

1.  Quantitative analysis of the packaging capacity of recombinant adeno-associated virus.

Authors:  J Y Dong; P D Fan; R A Frizzell
Journal:  Hum Gene Ther       Date:  1996-11-10       Impact factor: 5.695

Review 2.  Adeno-associated virus vectors in clinical trials.

Authors:  Barrie J Carter
Journal:  Hum Gene Ther       Date:  2005-05       Impact factor: 5.695

3.  DNA Damage Signaling Is Required for Replication of Human Bocavirus 1 DNA in Dividing HEK293 Cells.

Authors:  Xuefeng Deng; Peng Xu; Wei Zou; Weiran Shen; Jianxin Peng; Kaiyu Liu; John F Engelhardt; Ziying Yan; Jianming Qiu
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

4.  Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered.

Authors:  Maria P Limberis; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-22       Impact factor: 11.205

5.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

6.  Parvovirus Expresses a Small Noncoding RNA That Plays an Essential Role in Virus Replication.

Authors:  Zekun Wang; Weiran Shen; Fang Cheng; Xuefeng Deng; John F Engelhardt; Ziying Yan; Jianming Qiu
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

7.  A novel chimeric adenoassociated virus 2/human bocavirus 1 parvovirus vector efficiently transduces human airway epithelia.

Authors:  Ziying Yan; Nicholas W Keiser; Yi Song; Xuefeng Deng; Fang Cheng; Jianming Qiu; John F Engelhardt
Journal:  Mol Ther       Date:  2013-07-30       Impact factor: 11.454

8.  Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

Authors:  Richard B Moss; Carlos Milla; John Colombo; Frank Accurso; Pamela L Zeitlin; John P Clancy; L Terry Spencer; Joseph Pilewski; David A Waltz; Henry L Dorkin; Thomas Ferkol; Mark Pian; Bonnie Ramsey; Barrie J Carter; Dana B Martin; Alison E Heald
Journal:  Hum Gene Ther       Date:  2007-08       Impact factor: 5.695

9.  Anthracyclines, proteasome activity and multi-drug-resistance.

Authors:  Mirela R Fekete; William H McBride; Frank Pajonk
Journal:  BMC Cancer       Date:  2005-09-13       Impact factor: 4.430

10.  Human bocavirus and acute wheezing in children.

Authors:  Tobias Allander; Tuomas Jartti; Shawon Gupta; Hubert G M Niesters; Pasi Lehtinen; Riikka Osterback; Tytti Vuorinen; Matti Waris; Annelie Bjerkner; Annika Tiveljung-Lindell; Bernadette G van den Hoogen; Timo Hyypiä; Olli Ruuskanen
Journal:  Clin Infect Dis       Date:  2007-02-14       Impact factor: 9.079

View more
  16 in total

1.  Establishment of a High-Yield Recombinant Adeno-Associated Virus/Human Bocavirus Vector Production System Independent of Bocavirus Nonstructural Proteins.

Authors:  Ziying Yan; Wei Zou; Zehua Feng; Weiran Shen; Soo Yeun Park; Xuefeng Deng; Jianming Qiu; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2019-01-31       Impact factor: 5.695

2.  Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.

Authors:  Yinghua Tang; Ziying Yan; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2020-04-15       Impact factor: 5.695

3.  Impact of Natural or Synthetic Singletons in the Capsid of Human Bocavirus 1 on Particle Infectivity and Immunoreactivity.

Authors:  Julia Fakhiri; Kai-Philipp Linse; Mario Mietzsch; Man Xu; Marc A Schneider; Michael Meister; Oliver Schildgen; Paul Schnitzler; Maria Soderlund-Venermo; Mavis Agbandje-McKenna; Dirk Grimm
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

Review 4.  Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.

Authors:  Julia Fakhiri; Dirk Grimm
Journal:  Mol Ther       Date:  2021-04-05       Impact factor: 11.454

Review 5.  Advances in gene therapy for cystic fibrosis lung disease.

Authors:  Ziying Yan; Paul B McCray; John F Engelhardt
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 5.121

Review 6.  New Directions in Pulmonary Gene Therapy.

Authors:  Amber Vu; Paul B McCray
Journal:  Hum Gene Ther       Date:  2020-09       Impact factor: 4.793

7.  Establishment of a Recombinant AAV2/HBoV1 Vector Production System in Insect Cells.

Authors:  Xuefeng Deng; Wei Zou; Ziying Yan; Jianming Qiu
Journal:  Genes (Basel)       Date:  2020-04-17       Impact factor: 4.096

Review 8.  Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward.

Authors:  Ashley L Cooney; Paul B McCray; Patrick L Sinn
Journal:  Genes (Basel)       Date:  2018-11-07       Impact factor: 4.096

Review 9.  Recent Advances in Molecular Biology of Human Bocavirus 1 and Its Applications.

Authors:  Liting Shao; Weiran Shen; Shengqi Wang; Jianming Qiu
Journal:  Front Microbiol       Date:  2021-06-16       Impact factor: 5.640

10.  An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy.

Authors:  Gregg A Duncan; Namho Kim; Yanerys Colon-Cortes; Jason Rodriguez; Marina Mazur; Susan E Birket; Steven M Rowe; Natalie E West; Alessandra Livraghi-Butrico; Richard C Boucher; Justin Hanes; George Aslanidi; Jung Soo Suk
Journal:  Mol Ther Methods Clin Dev       Date:  2018-03-22       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.